Wednesday, February 5, 2020 / Categories: SDCC, ChiLDReN, Plain Language Summary, Pubs Maintenance Exome Sequencing in Individuals with Isolated Biliary Atresia Biliary atresia (BA) is a severe pediatric liver disease resulting in obliteration of the extrahepatic biliary tree. BA presents within the first few months of life as either an isolated finding or with additional features. The cause of isolated BA is unknown, with evidence for infectious, environmental, and genetic risk factors described. However, to date, there are no definitive causal genes identified for isolated BA in humans, and the question of whether single gene defects play a major role remains open. We performed exome-sequencing in 101 North American patients of European descent with isolated BA (including 30 parent-child trios) and considered several experimental designs to identify potentially deleterious protein-altering variants that may be involved in the disease. In a case-only analysis, we did not identify genes with variants shared among more than two probands, and burden tests of rare variants using a case-case control design did not yield significant results. In the trio analysis of 30 families (patient and parent trios), we identified 66 new variants in 66 genes including potentially deleterious variants in STIP1 and REV1. STIP1 is a chaperone for the heat-shock protein, HSP90, and has been shown to have diverse functions in yeast, flies and mammals, including stress-responses. REV1 is known to be a key player in DNA repair pathway and to interact with HSP90. In conclusion, our results do not support the hypothesis that a simple genetic model is responsible for the majority of cases of isolated BA. Our finding of de novo variants in genes linked to evolutionarily conserved stress responses (STIP1 and REV1) suggests that exploration of how genetic susceptibility and environmental exposure may interact to cause BA is warranted. Previous Article Gene Expression Signatures Associated with Survival Times of Pediatric Patients with Biliary Atresia Identify Potential Therapeutic Agents Next Article Impaired Redox and Protein Hemeostasis as Risk Factors and Therapeutic Targets in Toxin-Induced Biliary Atresia Print
DOPPS Program Spring Scientific Update Meeting via webinar on Friday, June 9th from 8am – 11am Wednesday, May 31, 2023
Arbor Research Collaborative for Health Welcomes New Vice President (VP) of Research, Dr. Cori Sheedy Thursday, April 6, 2023
Arbor Research Collaborative for Health Welcomes Research Scientist, Dr. Christine Stanik Wednesday, February 15, 2023
Arbor Research Awarded a $1.5M Contract to Support AHRQ in Developing their Patient-Centered Outcomes Research Trust Fund (PCORTF) Strategic Plan Thursday, December 8, 2022
Arbor Research Collaborative for Health Awarded $1.2 Million Contract from CDC to Help Nursing Homes Use Electronic Health Records to Report Healthcare Acquired Infections Thursday, October 20, 2022
Arbor Research Collaborative for Health to Serve on Team Evaluating the End-Stage Renal Disease Treatment Choices Model and the Kidney Care Choices Model Friday, September 16, 2022
Arbor Research Collaborative for Health Announces Partnership with Altarum to Support and Evaluate the National Hypertension Control Initiative Tuesday, April 26, 2022
Arbor Research Collaborative for Health Announces Hire of Chauncey Lynch, BS, as Vice President of Finance & Chief Financial Officer Monday, March 28, 2022
PDOPPS: International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival Friday, March 18, 2022
Arbor Research Collaborative for Health Announces Hire of Shanthy Edward, M.A., Psy.D. as Vice President of Strategic Growth & Chief Growth Officer Monday, March 7, 2022